Findings

What do systematic reviews say?

3,018 questions · 3,100 findings · 369 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 774 · 25%GRADE not reported 108 · 3.5%Very low 727 · 23.5%Low 840 · 27.1%Moderate 474 · 15.3%High 177 · 5.7%

Fluocinonide 0.05% vs hydrocortisone 1%

Relapse · people with discoid lupus erythematosus

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Fluocinonide 0.05% vs hydrocortisone 1%

Adverse events of medication, leading to discontinuation or significant morbidity · people with discoid lupus erythematosus

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 78 participants
Moderate

CoronaVac – Sinovac vs placebo

Confirmed SARS‐CoV‐2 infection

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

CoronaVac – Sinovac vs placebo

Confirmed symptomatic COVID‐19b

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 19852 participants
Low

CoronaVac – Sinovac vs placebo

Severe or critical COVID‐19

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 19852 participants
Low

CoronaVac – Sinovac vs placebo

All‐cause mortalityh

CoronaVac – Sinovac showed no clear difference in all‐cause mortalityh compared with placebo (low certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.5 [0.05, 5.52]
2 studies · 22610 participants
Low

CoronaVac – Sinovac vs placebo

Systemic reactogenicity events

CoronaVac – Sinovac showed no clear difference in systemic reactogenicity eventsj compared with placebo (low certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 1.19 [1, 1.42]
6 studies · 23966 participants
Low

CoronaVac – Sinovac vs placebo

Any adverse evento

CoronaVac – Sinovac leads to higher any adverse evento compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 1.09 [1.07, 1.11]
6 studies · 23367 participants
High

CoronaVac – Sinovac vs placebo

Serious adverse eventsr

CoronaVac – Sinovac showed no clear difference in serious adverse eventsr compared with placebo (low certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.97 [0.62, 1.51]
4 studies · 23139 participants
Low

CoronaVac – Sinovac vs placebo

Local reactogenicity events

CoronaVac – Sinovac leads to higher local reactogenicity eventsj compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 1.76 [1.69, 1.82]
6 studies · 23962 participants
High

3,4‐Diaminopyridine vs placebo

Muscle strength · participants with Lambert‐Eaton myasthenic syndrome

1 finding from 1 review

Treatment for Lambert‐Eaton myasthenic syndrome 2011 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 40 participants
Moderate

3,4‐Diaminopyridine vs placebo

Improvement in mean CMAP amplitude (mV) · participants with Lambert‐Eaton myasthenic syndrome

1 finding from 1 review

Treatment for Lambert‐Eaton myasthenic syndrome 2011 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 94 participants
High

3,4‐Diaminopyridine vs placebo

Adverse events · participants with Lambert‐Eaton myasthenic syndrome

1 finding from 1 review

Treatment for Lambert‐Eaton myasthenic syndrome 2011 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 42 participants
High

Group A: amino acids vs placebo

Prodromal symptoms: transition to psychosis Endpoint data (events) · people in the prodromal stage of psychosis

It is very uncertain whether group A: amino acids changes prodromal symptoms: transition to psychosis Endpoint data (events) compared with placebo (very low certainty).

1 finding from 1 review

Interventions for prodromal stage of psychosis 2019 · Cochrane Headline outcomes only
RR 0.48 [0.08, 2.98]
2 studies · 52 participants
Very low

Group A: amino acids vs placebo

Global state: clinically important change in global state · people in the prodromal stage of psychosis

1 finding from 1 review

Interventions for prodromal stage of psychosis 2019 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Group A: amino acids vs placebo

Mental state: psychosis risk symptoms SOPS total (higher score = worse, scale from: 0‐114) · people in the prodromal stage of psychosis

1 finding from 1 review

Interventions for prodromal stage of psychosis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 8 participants
Very low

Group A: amino acids vs placebo

Behaviour: clinically important change in behaviour · people in the prodromal stage of psychosis

1 finding from 1 review

Interventions for prodromal stage of psychosis 2019 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Group A: amino acids vs placebo

Adverse effects: suicidal thoughts (events) · people in the prodromal stage of psychosis

It is very uncertain whether group A: amino acids changes adverse effects: suicidal thoughts Short‐term (events) compared with placebo (very low certainty).

1 finding from 1 review

Interventions for prodromal stage of psychosis 2019 · Cochrane Headline outcomes only
RR 3.57 [0.15, 83.14]
1 study · 44 participants
Very low

Group A: amino acids vs placebo

Quality of life: clinically important change in quality of life · people in the prodromal stage of psychosis

1 finding from 1 review

Interventions for prodromal stage of psychosis 2019 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Group A: amino acids vs placebo

Satisfaction with treatment: leaving the study early Endpoint data (events) · people in the prodromal stage of psychosis

It is very uncertain whether group A: amino acids changes satisfaction with treatment: leaving the study early Endpoint data… compared with placebo (very low certainty).

1 finding from 1 review

Interventions for prodromal stage of psychosis 2019 · Cochrane Headline outcomes only
RR 0.96 [0.55, 1.69]
2 studies · 52 participants
Very low